FDA approves Novo Nordisk diabetes drug Ozempic

Jimmy 3x3 | 6 Views | 2017-12-05T18:25:48+00:00

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S’s diabetes drug Ozempic, setting the stage for a heated competitive battle with Eli Lilly & Co’s Trulicity.

FILE PHOTO: Novo Nordisk logo is seen in Bagsvaerd outside of Copenhagen, Denmark February 1, 2017. Scanpix Denmark/Liselotte Sabroe via REUTERS

Ozempic, known generically as semaglutide, will compete with others in a class known as glucagon-like peptide-1 (GLP-1) analogs, which imitate an intestinal hormone that stimulates the production of insulin.

Reporting by Toni Clarke in WashingtonEditing by Chizu Nomiyama

Our Standards:The Thomson Reuters Trust Principles.

Read Full News Here